Korean J Intern Med.
2021 May;36(3):544-556. 10.3904/kjim.2018.329.
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
- Affiliations
-
- 1Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea
- 2Medical Research Institute, Pusan National University Hospital, Busan, Korea
- 3Department of Laboratory Medicine, Pusan National University School of Medicine Busan, Korea
- KMID: 2515686
- DOI: http://doi.org/10.3904/kjim.2018.329
Abstract
- Background/Aims
Real-world, clinical practice data are lacking about sofosbuvir/ ribavirin (SOF/RBV) treatment of Korean patients with hepatitis C virus genotype 2 (HCV GT2) infection. This study investigated the efficacy and safety of SOF/RBV in Korean patients with HCV GT2 infection and clinical factors predicting sustained virological response 12 weeks (SVR12) after the end of SOF/RBV treatment.
Methods
A total of 181 patients with HCV GT2 with/without cirrhosis were treated with SOF/RBV for 16/12 weeks. Rapid virological response (RVR) was defined as non-detectable HCV RNA at 4 weeks.
Results
The RVR rate was 80.7% (146/181), the end of treatment response rate was 97.8% (177/181) and the SVR12 rate was 92.8% (168/181). Of eight patients with relapse, four did not achieve RVR. Three patients had a history of hepatocellular carcinoma (HCC). Multivariable analysis showed that RVR (p = 0.015) and no previous history of HCC (p = 0.007) were associated with SVR12. Factors significantly contributing to RVR included cirrhosis, creatinine concentration, and pre-treatment HCV RNA level. SVR12 rate was significantly higher in RVR (+) than RVR (–) patients (95.2% vs. 82.9%, p = 0.011) and also significantly higher in patients without than with a history of HCC (94.1% vs. 72.7%, p = 0.008). During treatment, 80/181 patients (44.2%) experienced mild to moderate adverse events, with 32 (17.7%) requiring RBV dose reductions due to anemia.
Conclusions
SOF/RBV treatment was effective and tolerable in HCV GT2 patients. RVR and no previous history of HCC were positive predictors of SVR12.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
- Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
- Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment
- Durability of antiviral therapy for chronic hepatitis C after achieving sustained virological response
- Can Non-invasive Fibrosis Assessment Predict Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients?
